In the realm of mental health treatments, Intravenous (IV) Ketamine therapy has emerged as a promising solution, particularly for treatment-resistant depression.

Ketamine, originally an anesthetic, has shown antidepressant effects as early as 1975. It’s now being actively studied and used for treatment-resistant depression, a condition where standard treatments fail to alleviate symptoms, in addition to other mental health diagnoses.

So, how does IV Ketamine work? Unlike standard antidepressants that increase serotonin levels, ketamine works differently. It’s believed to increase the levels of a chemical called brain-derived neurotrophic factor (BDNF) in the brain. BDNF promotes the growth and survival of neurons, and low levels of BDNF have been linked to various mental health disorders.

Ketamine induces the production of glutamate, a neurotransmitter in the brain. Abnormal levels of glutamate have been associated with depression. The increased glutamate leads the brain to form new connections and repair damaged ones, enhancing its adaptability.
Ketamine also causes physical growth in areas of the brain associated with emotion regulation and mental health disorders. It establishes new connections among neurons while repairing damaged cells. This results in new pathways in the brain that improve function in areas of mood, function, sleep, and others.

The administration of IV Ketamine starts with six doses over 2 to 3 weeks, possibly followed by weekly, then monthly, and then hopefully tapering off. It’s delivered in low doses and can provide rapid relief of treatment-resistant depression lasting for days to weeks.
IV Ketamine therapy is a breakthrough in mental health treatment. It offers hope for those grappling with treatment-resistant depression and potentially other mental health conditions. As research continues, the future of mental health treatment looks brighter with the promise of IV Ketamine therapy.